Recourt, Kasper
de Boer, Peter
Zuiker, Rob http://orcid.org/0000-0001-5604-0157
Luthringer, Remy
Kent, Justine
van der Ark, Peter
Van Hove, Ilse
van Gerven, Joop
Jacobs, Gabriel
van Nueten, Luc
Drevets, Wayne
Funding for this research was provided by:
Janssen Pharmaceuticals (42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001, 42847922MDD1001)
Article History
Received: 21 March 2019
Revised: 25 June 2019
Accepted: 11 August 2019
First Online: 3 September 2019
Change Date: 2 October 2019
Change Type: Correction
Change Details: In the original Article, Tables two and three had formatting issues which affected their clarity. This has been corrected in the PDF and HTML versions of this Article.
Conflict of interest
: The current study was funded by Janssen Research and Development, which also provided the study medication. P.d.B., P.v.d.A., I.V.H. and L.v.N., and W.C.D. are employees of Janssen and own Johnson and Johnson equity. J.K. is an employee of Sunovion, and owns Sunovion equity. R.L. is a Minerva Neurosciences employee and owns Minerva Neurosciences equity. The remaining authors declare that they have no conflict of interest.